Agreement signed with partners in USA, Canada, Czech Republic, Slovakia, Malaysia, Singapore
POA Pharma Scandinavia AB signs distribution agreements, with three new partners, in six countries for marketing and sale of products
News
- Home
- News
POA Pharma Update
ONE Generic product launched TWO Products for out licensing THREE 3 new Rx for Launch 2014, at least FOUR Nordic
New study on Antisecretory Factor in regards to Menière’s Disease 6 out of 10 significantly improved
Antisecretory Factor–Inducing Therapy Improves Patient-Reported Functional Levels in Meniere’s Disease Samuel C. Leong, MPhil, FRCS(ORL-HNS); Surya Narayan, MS, DLO, FRCS(ORL-HNS);
POA launches first sterile single use ampules for use against infections in the ear
Cetraxal 2 mg/ml are antibiotic ear drops for use against infections in the ear. Cetraxal 2 mg/ml consists of 15
Poa lanserer første engångspipetten for behandling av infeksjonssykdommer i den ytre øregangen
Cetraxal 2 mg/ml er antibiotika øredråper som brukes til infeksjonssykdommer i den ytre øregangen. Cetraxal 2 mg/ml består av 15
Poa lanserer første engångspipetten for behandling av infeksjonssykdommer i den ytre øregangen
Cetraxal 2 mg/ml er antibiotika øredråper som brukes til infeksjonssykdommer i den ytre øregangen. Cetraxal 2 mg/ml består av 15
Poa lancerer første engångspipetten til behandling avinfeksjonssykdommer i den ytre øregangen
Cetraxal 2 mg/ml er antibiotika øredråper som brukes til infeksjonssykdommer i den ytre øregangen. Cetraxal 2 mg/ml består av 15
POA lanserar första engångspipetten för behandling av infektionssjukdomar i den yttre hörselgången.
Cetraxal 2 mg/ml är örondroppar, med antibiotika, som används för infektionssjukdomar i den yttre hörselgången. Cetraxal 2 mg/ml består av
POA signs distribution Agreement for UK and Ireland
POA Pharma Scandinavia AB have signed an agreement with UK Based Mitovie Ltd (http://www.mitovie.com)regarding SPC Flakes® and Salovum® for Ireland and the
News: Emselex
Emselex®/Enablex® (darifenacin) is a branded prescription medicine in extended release tablet form which is a muscarinic antagonist indicated for the
New Randomised double-blinded, placebo-controlled, cross-over study regarding SPC Flakes
Anti-secretory factor-inducing therapy improves patient reported functional levels in Meniere's disease. 1Samuel C. Leong MPhil FRCS(ORL-HNS) 2Surya Narayan MS DLO
POA Pharma and launches SPC Flakes and Salovum in Italy
Together with our distributor in Italy, PIAM FARMACEUTICI S.P.A we introduced SPC Flakes and Salovum at the yearly domestic Gastr congress
Onytec®
The active ingredient in Onytec ® is ciclopirox, which is active against a broad spectrum of dermatophytes, yeasts, molds and
POA Pharma Scandinavia lancerer det første nye lægemiddel til lokal behandling af neglesvamp i 10 år
Første nye lægemiddel til behandling af neglesvamp i 10 år! Har svampen først fået fæste under neglebåndet kan det være
POA Pharma Scandinavia lanserar första nya läkemedlet för lokal behandling av Nagelsvamp, på 10 år.
Första nya läkemedlet vid behandling av Nagelsvamp på 10 år! Om först svampen har fått fäste under nagelbandet är en
POA PHARMA SCANDINAVIA SIGNS DISTRIBUTION AGREEMENT FOR NORTHERN EUROPE WITH MERUS LABS
Toronto/Gothenburg, January 17, 2013 – Merus Labs International Inc [TSX: MSL, NASDAQ: MSLI] is pleased to announce that through its
WHAT A YEAR IT HAS BEEN AND WHAT A YEAR IT CAN BE
WHAT A YEAR IT HAS BEEN AND WHAT A YEAR IT CAN B In December 2010,POA Pharma Scandinavia AB was
POA Pharma Scandinavia, Social Media
wwww.poapharma.com POA Pharma Scandinavia Website. Info about POA pharma, Products, Principals and news. English and Scandinavian language. http://linkd.in/Stay4V Follow
Eighteen months from start
Status September 2012: Distribution and Marketing in Denmark, Finland, Holland,Island, Norway and Sweden. Representing 15 producers from 9 different countries.
POA PHARMA SCANDINAVIA and SALVAT HAVE SIGNED A LICENSING AGREEMENT for THE NORDIC REGION
POA PHARMA SCANDINAVIA and SALVAT HAVE SIGNED A LICENSING AGREEMENT FOR THE DISTRIBUTION AND SALE OF PRODUCTS WITHIN THE COMPETENCE